amsacrine has been researched along with Skin Neoplasms in 5 studies
Amsacrine: An aminoacridine derivative that intercalates into DNA and is used as an antineoplastic agent.
amsacrine : A sulfonamide that is N-phenylmethanesulfonamide substituted by a methoxy group at position 3 and an acridin-9-ylamino group at position 4. It exhibits antineoplastic activity.
Skin Neoplasms: Tumors or cancer of the SKIN.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a phase II study 20 patients with measurable metastatic melanoma were treated with amsacrine 120 mg/m2 every 3 weeks." | 7.67 | Chemotherapy in metastatic melanoma: phase II studies of amsacrine, mitoxantrone and bisantrene. ( Bishop, J; Coates, AS; Mann, GJ; Raghavan, D, 1986) |
| "In a phase II study 20 patients with measurable metastatic melanoma were treated with amsacrine 120 mg/m2 every 3 weeks." | 3.67 | Chemotherapy in metastatic melanoma: phase II studies of amsacrine, mitoxantrone and bisantrene. ( Bishop, J; Coates, AS; Mann, GJ; Raghavan, D, 1986) |
| "Amsacrine is an antineoplastic drug used in the treatment of acute adult leukemias." | 1.29 | Carcinogenicity of the anticancer topoisomerase inhibitor, amsacrine, in Wistar rats. ( Courtney, CL; Gough, AW; Graziano, MJ; Kheoh, T; Meierhenry, EF; Pegg, DG, 1996) |
| "Leukopenia was the dose-limiting toxicity with 7." | 1.27 | The treatment of melanoma with m-AMSA. A Cancer and Leukemia Group B phase II study. ( Amrein, PC; Carey, RW; Coleman, M; Green, MR; Holland, JF; Kennedy, BJ; Poulin, RF; Richards, F; Weil, M; Weinberg, V, 1984) |
| "Leukopenia was found to be dose-limiting; thrombocytopenia and anemia were also observed." | 1.26 | Phase II study of m-AMSA in advances malignant melanoma. ( Arseneau, JC; Kuperminc, M; Probert, JC; Wolter, JM, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (80.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amrein, PC | 1 |
| Poulin, RF | 1 |
| Coleman, M | 1 |
| Richards, F | 1 |
| Weil, M | 1 |
| Kennedy, BJ | 1 |
| Carey, RW | 1 |
| Green, MR | 1 |
| Holland, JF | 1 |
| Weinberg, V | 1 |
| Legha, SS | 1 |
| Hall, SW | 1 |
| Powell, KC | 1 |
| Burgess, MA | 1 |
| Benjamin, RS | 1 |
| Gutterman, JU | 1 |
| Bodey, GP | 1 |
| Arseneau, JC | 1 |
| Wolter, JM | 1 |
| Probert, JC | 1 |
| Kuperminc, M | 1 |
| Graziano, MJ | 1 |
| Courtney, CL | 1 |
| Meierhenry, EF | 1 |
| Kheoh, T | 1 |
| Pegg, DG | 1 |
| Gough, AW | 1 |
| Coates, AS | 1 |
| Bishop, J | 1 |
| Mann, GJ | 1 |
| Raghavan, D | 1 |
5 other studies available for amsacrine and Skin Neoplasms
| Article | Year |
|---|---|
The treatment of melanoma with m-AMSA. A Cancer and Leukemia Group B phase II study.
Topics: Adult; Aged; Aminoacridines; Amsacrine; Antineoplastic Agents; Drug Evaluation; Female; Humans; Leuk | 1984 |
Phase II study of 4'-(9-acridinylamino) methanesulfon-m- anisidide (AMSA) in metastatic melanoma.
Topics: Adult; Aged; Aminoacridines; Amsacrine; Antineoplastic Agents; Drug Administration Schedule; Drug Ev | 1980 |
Phase II study of m-AMSA in advances malignant melanoma.
Topics: Adult; Aged; Aminoacridines; Amsacrine; Drug Evaluation; Female; Humans; Leukopenia; Male; Melanoma; | 1982 |
Carcinogenicity of the anticancer topoisomerase inhibitor, amsacrine, in Wistar rats.
Topics: Amsacrine; Animals; Antineoplastic Agents; Carcinogenicity Tests; Carcinogens; Drug Evaluation, Prec | 1996 |
Chemotherapy in metastatic melanoma: phase II studies of amsacrine, mitoxantrone and bisantrene.
Topics: Aminoacridines; Amsacrine; Anthracenes; Anthraquinones; Antineoplastic Agents; Drug Evaluation; Fema | 1986 |